S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

CTI BioPharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.0% Downside
$9.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.25) to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.04 out of 5 stars

Medical Sector

913th out of 918 stocks

Pharmaceutical Preparations Industry

399th out of 402 stocks

CTIC stock logo

About CTI BioPharma Stock (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTIC Stock News Headlines

Connect Biopharma Holdings Ltd (CNTB)
Theravance Biopharma Inc TBPH
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
CTI Engineering Co Ltd (9621)
Sobi completes acquisition of CTI BioPharma Corp.
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Stifel Nicolaus upgrades CTI BioPharma (CTIC) to a Hold
JMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)
SVB Securities downgrades CTI BioPharma (CTIC) to a Hold
The Latest Analyst Ratings for CTI BioPharma
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
127
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
-1.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Adam R. Craig M.B.A. (Age 57)
    M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director
    Comp: $1.09M
  • Mr. David H. Kirske (Age 69)
    Exec. VP, CFO & Sec.
    Comp: $590.41k
  • Mr. James K. Fong (Age 61)
    Exec. VP & Chief Commercial Officer
    Comp: $597.3k
  • Mr. Ed Bell
    Sr. Director of Investor Relations
  • Mr. Bruce K. Bennett Jr. (Age 71)
    Sr. VP Global Pharmaceutical Operations
  • Mr. John P. Volpone
    Exec. VP & Chief of Staff
  • Dr. Jennifer A. Smith
    Sr. VP of Biometrics

CTIC Stock Analysis - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price target for 2024?

5 brokerages have issued 12-month target prices for CTI BioPharma's stock. Their CTIC share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 1.0%.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to the consensus estimate of $24.88 million. During the same period last year, the company earned ($0.38) earnings per share.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

This page (NASDAQ:CTIC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners